Channel blocker explained

A channel blocker is the biological mechanism in which a particular molecule is used to prevent the opening of ion channels in order to produce a physiological response in a cell. Channel blocking is conducted by different types of molecules, such as cations, anions, amino acids, and other chemicals. These blockers act as ion channel antagonists, preventing the response that is normally provided by the opening of the channel.

Ion channels permit the selective passage of ions through cell membranes by utilizing proteins that function as pores, which allow for the passage of electrical charge in and out of the cell.[1] These ion channels are most often gated, meaning they require a specific stimulus to cause the channel to open and close. These ion channel types regulate the flow of charged ions across the membrane and therefore mediate membrane potential of the cell.

Molecules that act as channel blockers are important in the field of pharmacology, as a large portion of drug design is the use of ion channel antagonists in regulating physiological response. The specificity of channel block molecules on certain channels makes it a valuable tool in the treatment of numerous disorders.

Background

Ion channels

See main article: article and Ion channel. To comprehend the mechanism of channel blockers, it is critical to understand the composition of ion channels. Their main function is to contribute to the resting membrane potential of a cell via the flow of ions through a cell membrane. To accomplish this task, ions must be able to cross the hydrophobic region of a lipid bilayer membrane, an unfavorable process. To assist in ion transport, ion channels form a hydrophilic pore through the membrane which allows for the usually unfavorable transfer of hydrophilic molecules.[2] Various ion channels have varying mechanisms of function. They include:

Molecules that act as ion channel blockers can be used in relation to any of these various channels. For example, sodium channels, which are essential to the production of action potentials, are affected by many different toxins. Tetrodotoxin (TTX), a toxin found in pufferfish, completely blocks sodium ion transportation by blocking the selectivity filter region of the channel.[3] Much of the structure of the pores of ion channels has been elucidated from studies that used toxins to inhibit channel function.[4] [5] [6]

Identity

Tools such as X-ray crystallography and electrophysiology have been essential in locating the binding sites of open channel block molecules. By studying the biological and chemical makeup of ion channels, researchers can determine the makeup of the molecules that bind to certain regions. X-ray crystallography provides a structural image of the channel and molecule in question.[7] Determining the hydrophobicity of channel domains through hydrophobicity plots also provides clues to the chemical makeup of the molecule and why it binds to a certain region. For example, if a protein binds to a hydrophobic region of the channel (and therefore, has a transmembrane region), the molecule in question might be composed of the amino acids alanine, leucine, or phenylalanine, as they are all hydrophobic themselves.[8] Electrophysiology is also an important tool in identifying channel structure, as analyzing the ionic factors that lead to channel activation can be critical to understanding the inhibiting actions of open channel block molecules.

Physiology

Receptor antagonist

Channel blockers are antagonists for the respective ion channels. Many channels have binding spots for regulatory elements which can promote or repress normal function depending on the requirements within the cell and organism. The normal function of agonist binding is the generation of cellular changes leading to various downstream effects; these effects range from altering membrane potential to initiation of signaling cascades.[9] Conversely, when open channel blockers bind to the cell they prevent the normal function of agonist binding. For example, voltage-gated channels open and close based on membrane potential and are critical in the generation of action potentials by their allowance of ions to flow down established gradients. However, open channels blockers can bind to these channels to prevent ions from flowing, thus inhibiting the initiation of an action potential.[10]

Specificity of molecules

Many different organic compounds can act as channel blockers despite channel specificity. Channels have evolved structures that, due to their membrane spanning regions, can discriminate between various ions or compounds. For example, some objects are too large for to fit into channels that are structurally specified to transport smaller objects, such as a potassium ion attempting to fit into a sodium channel. Conversely, some objects are too small to be properly stabilized by certain channel pores, such as a sodium ion attempting to pass through a potassium channel.[11] In both cases, channel flux is not permitted. However, as long as a particular compound possesses adequate chemical affinity to a channel, that compound may be able to bind and block the channel pore. For example, TTX can bind and inactivate voltage-gated sodium channels, despite the fact that TTX is much larger and chemically different than sodium ions. Given the disparities in size and chemical properties between TTX and a sodium ion, this is an example of structure being used to block usually specific channels. [12]

Kinetics

A channel block can be induced by many different types of organic compounds as long as they can bind to some portion of the target channel's pore. The kinetics of channel blockers are primarily understood though their use as anesthetics. Local anesthetics work by inducing a phasic block state in the targeted neurons. Initially, open channel blockers do not effectively prevent action potentials, as few channels are blocked and the blocker itself can be released from the channel either quickly or slowly depending on its characteristics. However, phasic blocks occur as repeated depolarization increases blockers’ affinity for channels in the neuron. The combination of an increase in available channels and the change in channel conformation to increase blocker binding affinity are responsible for this action.[13] [14]

Clinical significance

Therapeutic uses

Various neurodegenerative diseases have been associated with excessive NMDA receptor activation meant to mediate calcium dependent neurotoxicity. Researchers have examined many different NMDA antagonists and their therapeutic efficacy, none of which have concluded to be both safe and effective.[15] For years, researchers have been investigating the effects of an open channel block, memantine, as a treatment option for neurotoxicity. They have hypothesized that the faster blocking and unblocking rates, and overall kinetics, of memantine could be the underlying reason for the clinical tolerance. As an uncompetitive antagonist, memantine should bring NMDA levels close to normal despite high glutamate concentration. Based on this information, researchers have speculated that someday memantine could be used as an open channel block to prevent increasing glutamate levels associated with neurotoxicity with few to no side effects compared to other treatment options.

Alzheimer's disease

Alzheimer's disease, a specific neurodegenerative disorder, is linked to glutaminergic neurotransmission interruptions that are believed to result in the staple cognitive symptoms of Alzheimer's. Researchers suggest that noncompetitive NMDA receptor agonists can be used to aid in the management of these symptoms without producing severe side effects.[16] As one of the only drugs approved for Alzheimer's treatment, memantine has been shown to allow excitatory post-synaptic currents to remain unaffected while decreasing the incidence and amplitude of inhibitory post-synaptic currents.[17] Evidence supports the hypothesis that both the strong voltage dependency and fast kinetics of memantine may be responsible for the decreased side effects and cognitive progress.[18]

Cystic fibrosis

Cystic fibrosis is a progressive, genetic disease that is linked to CF transmembrane regulator (CFTR) dysfunction.[19] Blockage of this channel by certain cytoplasmic, negatively-charged substances results in reduced chloride ion and bicarbonate anion transport, as well as reduced fluid and salt secretion. This results in a buildup of thick mucus, which is characteristic of cystic fibrosis.

Pharmacology

Anesthetics

Channel blockers are essential in the field of anesthetics. Sodium channel inhibitors are used as both antiepileptics and antiarrhythmics, as they can inhibit the hyper-excitable tissues in a patient.[20] Introducing specific sodium channel blockers into a tissue allows for the preferential binding of the blocker to sodium channels, which results in an ultimate inhibition of the flow of sodium into the tissue. Over time, this mechanism leads to an overall decrease in tissue excitation. Prolonged hyperpolarization interrupts normal channel recovery and allows for constant inhibition, providing dynamic control of the anesthetics in a given setting.

Alzheimer's disease

Excessive exposure to glutamate leads to neurotoxicity in patients with Alzheimer's disease. Specifically, over-activation of NMDA-type glutamate receptors have been linked to neural cell excitotoxicity and cell death.[21] A potential solution to this is a decrease in NMDA receptor activity, without interfering so drastically as to cause clinical side effects.[22]

In an attempt to prevent further neurodegeneration, researchers have used memantine, an open channel block, as a form of treatment. Thus far, the use of memantine in patients with Alzheimer's disease quickly results in clinical progress across many different symptoms. Memantine is thought to work effectively due to its ability to quickly modify its kinetics, which prevents buildup in the channel and allows normal synaptic transmission. Other channel blockers have been found to block all NMDA receptor activity, leading to adverse clinical side effects.[23]

CFTR channel dysfunction

Cystic Fibrosis transmembrane regulators (CFTRs) function in chloride ion, bicarbonate anion, and fluid transport.[24] They are expressed primarily in apical membranes of epithelial cells in respiratory, pancreatic, gastrointestinal, and reproductive tissues. Abnormally-elevated CFTR function results in excessive fluid secretion. High-affinity CFTR inhibitors, such as CFTRinh-172 and GlyH-101, have been shown to be efficient in treatment of secretory diarrheas.[25] [26] Theoretically, CFTR channel blockers may also be useful as male contraceptives. CFTR channels mediate bicarbonate anion entry which is essential for sperm capacitation.[27]

Various types of substances have been known to block CFTR chloride ion channels. Some of the best-known and studied substances include sulfonylureas, arylaminobenzenoates, and disulfonic stilbenes.[28] [29] [30] These blockers are side-dependent as they enter the pore exclusively from the cytoplasmic side, voltage-dependent as hyperpolarized membrane potentials favor negatively-charged substance entry into the pore from the cytoplasmic side, and chloride ion concentration-dependent as high extracellular chloride ions electrostatically repel negatively-charged blockers back into the cytoplasm.[31]

Types

There are several different major classes of channel blockers, including:

The following types which act on ligand-gated ion channels (LGICs) via binding to their pore also exist:

Channel blockers are also known to act at AMPA receptors, Glycine receptors, Kainate receptors, P2X receptors and Zinc (Zn2+)-activated channels. The type of inhibition mediated by channel blockers may be referred to as noncompetitive or uncompetitive.

See also

Notes and References

  1. News: Medical Definition of Ion channel . MedicineNet . 2017-03-20 .
  2. Ahern CA, Payandeh J, Bosmans F, Chanda B . The hitchhiker's guide to the voltage-gated sodium channel galaxy . The Journal of General Physiology . 147 . 1 . 1–24 . January 2016 . 26712848 . 4692491 . 10.1085/jgp.201511492 .
  3. Moore JW, Blaustein MP, Anderson NC, Narahashi T . Basis of tetrodotoxin's selectivity in blockage of squid axons . The Journal of General Physiology . 50 . 5 . 1401–11 . May 1967 . 6033592 . 10.1085/jgp.50.5.1401 . 2225715.
  4. Stevens M, Peigneur S, Tytgat J . Neurotoxins and their binding areas on voltage-gated sodium channels . Frontiers in Pharmacology . 2 . 71 . 2011-11-09 . 22084632 . 3210964 . 10.3389/fphar.2011.00071 . free .
  5. Miller C . Competition for block of a Ca2(+)-activated K+ channel by charybdotoxin and tetraethylammonium . Neuron . 1 . 10 . 1003–6 . December 1988 . 2483092 . 10.1016/0896-6273(88)90157-2. 32262373 .
  6. Aiyar J, Withka JM, Rizzi JP, Singleton DH, Andrews GC, Lin W, Boyd J, Hanson DC, Simon M, Dethlefs B . Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins . Neuron . 15 . 5 . 1169–81 . November 1995 . 7576659 . 10.1016/0896-6273(95)90104-3. free .
  7. Findeisen F, Campiglio M, Jo H, Abderemane-Ali F, Rumpf CH, Pope L, Rossen ND, Flucher BE, DeGrado WF, Minor DL . Stapled Voltage-Gated Calcium Channel (CaV) α-Interaction Domain (AID) Peptides Act As Selective Protein-Protein Interaction Inhibitors of CaV Function . ACS Chemical Neuroscience . March 2017 . 28278376 . 10.1021/acschemneuro.6b00454 . 8 . 6 . 5481814 . 1313–1326.
  8. Phoenix DA, Harris F . The hydrophobic moment and its use in the classification of amphiphilic structures (review) . Molecular Membrane Biology . 19 . 1 . 1–10 . 2002-01-01 . 11989818 . 10.1080/09687680110103631. 19943697 . free .
  9. Jackson MB . Open channel block and beyond . The Journal of Physiology . 588 . Pt 4 . 553–4 . February 2010 . 20173077 . 2828128 . 10.1113/jphysiol.2009.183210 .
  10. Ahern CA, Payandeh J, Bosmans F, Chanda B . The hitchhiker's guide to the voltage-gated sodium channel galaxy . The Journal of General Physiology . 147 . 1 . 1–24 . January 2016 . 26712848 . 4692491 . 10.1085/jgp.201511492 .
  11. Butterworth JF, Strichartz GR . Molecular mechanisms of local anesthesia: a review . Anesthesiology . 72 . 4 . 711–34 . April 1990 . 2157353 . 10.1097/00000542-199004000-00022. 8277924 . free .
  12. Evans MH . Mechanism of saxitoxin and tetrodotoxin poisoning . British Medical Bulletin . 25 . 3 . 263–7 . September 1969 . 5812102 . 10.1093/oxfordjournals.bmb.a070715 .
  13. Mert T, Gunes Y, Guven M, Gunay I, Ozcengiz D . Comparison of nerve conduction blocks by an opioid and a local anesthetic . European Journal of Pharmacology . 439 . 1–3 . 77–81 . March 2002 . 11937095 . 10.1016/S0014-2999(02)01368-7 .
  14. Mitolo-Chieppa D, Carratu MR . Anaesthetic drugs: electrophysiological bases of their conduction blocking effect . Pharmacological Research Communications . 15 . 5 . 439–50 . May 1983 . 6351107 . 10.1016/s0031-6989(83)80064-2.
  15. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA . Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity . The Journal of Neuroscience . 12 . 11 . 4427–36 . November 1992 . 10.1523/JNEUROSCI.12-11-04427.1992 . 1432103 . 6576016 .
  16. Müller WE, Mutschler E, Riederer P . Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia . Pharmacopsychiatry . 28 . 4 . 113–24 . July 1995 . 7491365 . 10.1055/s-2007-979603 . 260240191 .
  17. Povysheva NV, Johnson JW . Effects of memantine on the excitation-inhibition balance in prefrontal cortex . Neurobiology of Disease . 96 . 75–83 . December 2016 . 27546057 . 5102806 . 10.1016/j.nbd.2016.08.006 .
  18. Dominguez. Evangelyn. Chin. Ting-Yu. Chen. Chih-Ping. Wu. Tzong-Yuan. 2011-12-01. Management of moderate to severe Alzheimer's disease: Focus on memantine. Taiwanese Journal of Obstetrics and Gynecology. English. 50. 4. 415–423. 10.1016/j.tjog.2011.10.004. 1028-4559. 22212311. free.
  19. Lubamba B, Dhooghe B, Noel S, Leal T . Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy . Clinical Biochemistry . 45 . 15 . 1132–44 . October 2012 . 22698459 . 10.1016/j.clinbiochem.2012.05.034 .
  20. Ramos E, O'leary ME . State-dependent trapping of flecainide in the cardiac sodium channel . The Journal of Physiology . 560 . Pt 1 . 37–49 . October 2004 . 15272045 . 1665201 . 10.1113/jphysiol.2004.065003 .
  21. Kocahan S, Doğan Z . Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors . Clinical Psychopharmacology and Neuroscience . 15 . 1 . 1–8 . February 2017 . 28138104 . 5290713 . 10.9758/cpn.2017.15.1.1 .
  22. Lipton SA . Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation . Current Drug Targets . 8 . 5 . 621–32 . May 2007 . 17504105 . 10.2174/138945007780618472.
  23. Lipton SA . Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults . NeuroRx . 1 . 1 . 101–10 . January 2004 . 15717010 . 534915 . 10.1602/neurorx.1.1.101 . Neuroprotection .
  24. Frizzell RA, Hanrahan JW . Physiology of epithelial chloride and fluid secretion . Cold Spring Harbor Perspectives in Medicine . 2 . 6 . a009563 . June 2012 . 22675668 . 3367533 . 10.1101/cshperspect.a009563 .
  25. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, Verkman AS . Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy . The Journal of General Physiology . 124 . 2 . 125–37 . August 2004 . 15277574 . 2229623 . 10.1085/jgp.200409059 .
  26. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS . Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion . The Journal of Clinical Investigation . 110 . 11 . 1651–8 . December 2002 . 12464670 . 151633 . 10.1172/JCI16112 .
  27. Chen H, Ruan YC, Xu WM, Chen J, Chan HC . Regulation of male fertility by CFTR and implications in male infertility . Human Reproduction Update . 18 . 6 . 703–13 . 2012-11-01 . 22709980 . 10.1093/humupd/dms027 . free .
  28. Schultz BD, DeRoos AD, Venglarik CJ, Singh AK, Frizzell RA, Bridges RJ . Glibenclamide blockade of CFTR chloride channels . The American Journal of Physiology . 271 . 2 Pt 1 . L192-200 . August 1996 . 8770056 . 10.1152/ajplung.1996.271.2.L192.
  29. Zhang ZR, Zeltwanger S, McCarty NA . Direct comparison of NPPB and DPC as probes of CFTR expressed in Xenopus oocytes . The Journal of Membrane Biology . 175 . 1 . 35–52 . May 2000 . 10811966 . 10.1007/s002320001053. 19341540 .
  30. Linsdell P, Hanrahan JW . Disulphonic stilbene block of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in a mammalian cell line and its regulation by a critical pore residue . The Journal of Physiology . 496 . Pt 3 . 687–93 . November 1996 . 8930836 . 1160856 . 10.1113/jphysiol.1996.sp021719.
  31. Linsdell P . Cystic fibrosis transmembrane conductance regulator chloride channel blockers: Pharmacological, biophysical and physiological relevance . World Journal of Biological Chemistry . 5 . 1 . 26–39 . February 2014 . 24600512 . 3942540 . 10.4331/wjbc.v5.i1.26 . free .